BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 30685099)

  • 1. Relation between baseline LDL-cholesterol and cardiovascular outcomes in high cardiovascular risk hypertensive patients: A post-hoc SPRINT data analysis.
    Nguyen LS; Procopi N; Salem JE; Squara P; Funck-Brentano C
    Int J Cardiol; 2019 Jul; 286():159-161. PubMed ID: 30685099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin Therapy in Patients With Low Serum Levels of Low-Density Lipoprotein Cholesterol.
    Tsujimoto T; Kajio H; Sugiyama T
    Am J Cardiol; 2017 Dec; 120(11):1947-1954. PubMed ID: 28951019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study.
    Van Ganse E; Souchet T; Laforest L; Moulin P; Bertrand M; Le Jeunne P; Chretin S; Yin D; Alemao E; de Pouvourville G
    Atherosclerosis; 2006 Mar; 185(1):58-64. PubMed ID: 16038912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact.
    Bauters C; Tricot O; Lemesle G; Meurice T; Hennebert O; Farnier M; Lamblin N
    Arch Cardiovasc Dis; 2018 Nov; 111(11):634-643. PubMed ID: 29198936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.
    Bangalore S; Fayyad R; Messerli FH; Laskey R; DeMicco DA; Kastelein JJ; Waters DD
    Am J Cardiol; 2017 Feb; 119(3):379-387. PubMed ID: 27939230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy.
    Presta V; Figliuzzi I; Miceli F; Coluccia R; Fogacci F; Cicero AFG; Ferrucci A; Borghi C; Volpe M; Tocci G;
    Atherosclerosis; 2019 Jun; 285():40-48. PubMed ID: 31003091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of blood lipid parameters variability with ischemic stroke in hypertensive patients.
    Huang YQ; Liu L; Liu XC; Lo K; Tang ST; Feng YQ; Zhang B
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1521-1532. PubMed ID: 33810958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors.
    Breuker C; Clement F; Mura T; Macioce V; Castet-Nicolas A; Audurier Y; Boegner C; Morcrette E; Jalabert A; Villiet M; Avignon A; Sultan A
    Int J Cardiol; 2018 Oct; 268():195-199. PubMed ID: 30041785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2.
    Natsuaki M; Furukawa Y; Morimoto T; Nakagawa Y; Ono K; Kaburagi S; Inada T; Mitsuoka H; Taniguchi R; Nakano A; Kita T; Sakata R; Kimura T;
    Circ J; 2012; 76(6):1369-79. PubMed ID: 22447012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan.
    Teramoto T; Uno K; Miyoshi I; Khan I; Gorcyca K; Sanchez RJ; Yoshida S; Mawatari K; Masaki T; Arai H; Yamashita S
    Atherosclerosis; 2016 Aug; 251():248-254. PubMed ID: 27419905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL.
    Averna M; Stroes E;
    Atheroscler Suppl; 2017 Apr; 26():16-24. PubMed ID: 28434480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
    Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
    Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of Statin Therapy in Patients With Acute Myocardial Infarction With Serum Low-Density Lipoprotein Cholesterol ≤ 50 mg/dl.
    Piao ZH; Jin L; Kim JH; Ahn Y; Kim YJ; Cho MC; Kim CJ; Kim HS; Liu B; Jeong MH;
    Am J Cardiol; 2017 Jul; 120(2):174-180. PubMed ID: 28532771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritonitis Affects the Relationship Between Low-Density Lipoprotein Cholesterol and Cardiovascular Events in Peritoneal Dialysis Patients.
    Ye H; Wu H; Peng Y; Zhou Q; Cao P; Guo Q; Mao H; Yu X; Yang X
    Can J Cardiol; 2020 Jan; 36(1):92-99. PubMed ID: 31785993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial.
    Zanchetti A; Liu L; Mancia G; Parati G; Grassi G; Stramba-Badiale M; Silani V; Bilo G; Corrao G; Zambon A; Scotti L; Zhang X; Wang H; Zhang Y; Zhang X; Guan TR; Berge E; Redon J; Narkiewicz K; Dominiczak A; Nilsson P; Viigimaa M; Laurent S; Agabiti-Rosei E; Wu Z; Zhu D; Rodicio JL; Ruilope LM; Martell-Claros N; Pinto F; Schmieder RE; Burnier M; Banach M; Cifkova R; Farsang C; Konradi A; Lazareva I; Sirenko Y; Dorobantu M; Postadzhiyan A; Accetto R; Jelakovic B; Lovic D; Manolis AJ; Stylianou P; Erdine S; Dicker D; Wei G; Xu C; Xie H; Coca A; O'Brien J; Ford G
    J Hypertens; 2014 Sep; 32(9):1888-97. PubMed ID: 24979303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.